Multimodality treatment of thymoma: a prospective study

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Research

Background:

• Thymomas are a diverse group of thoracic neoplasms with non-standardized treatment protocols for invasive types.
• This study aimed to establish a clinicopathologically guided protocol for multimodality therapy in thymoma management.

Purpose of the Study:

• To develop and evaluate a clinicopathologically based multimodality treatment protocol for thymomas.
• To improve therapeutic outcomes and survival rates for patients with invasive and malignant thymoma.

Main Methods:

• A retrospective analysis of 83 thymoma patients (1965-1988) informed the development of a multimodality protocol.
• The protocol was prospectively applied to 65 patients from 1989 onwards, categorizing them into benign (Group I), invasive (Group II), and malignant (Group III) thymoma groups.
• Treatment strategies included radical resection, adjuvant chemotherapy, radiotherapy, neoadjuvant chemotherapy, and biopsy based on tumor type and stage.

Main Results:

• The 8-year survival rates for stages I, II, III, and IV thymoma were 95%, 100%, 92%, and 68%, respectively.
• Patients in Group III (malignant thymoma) showed a significant improvement in 8-year survival from 43% to 76% (p < 0.049) after implementing the multimodality protocol.
• Overall survival rates for medullary, mixed, and cortical thymomas were 92%, 100%, and 85%, respectively.

Conclusions:

• Multimodality treatment, incorporating neoadjuvant chemotherapy and adjuvant chemoradiotherapy, enhances outcomes for invasive and malignant thymoma.
• The proposed clinicopathologically based protocol offers a standardized approach to improve survival in thymoma patients.